Senator Ted Cruz, R-Texas, has reintroduced a bill he thinks will speed US approval of drugs, biologics, or devices approved in other countries.
Senator Ted Cruz, R-Texas, reintroduced a bill he thinks will speed US approval of drugs, biologics, or devices approved in other countries.
The bill, called Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act, or the RESULTS Act, would give the Food and Drug Administration (FDA) 30 days after a company sends in an application to decide whether it wants to greenlight a drug, device, or biologic approved in another country.
It’s at least the third time Cruz has introduced the bill (the last 2 times were in 2015 and 2017), which would give Congress the power to override an FDA rejection of a product. The 2 other cosponsors are Senators Ron Johnson, R-Wisconsin, and Mike Lee, R-Utah.
Cruz has said the bill could put downward pressure on the prices of drugs and devices as well as alleviate drug shortages.
The bill orders the FDA to review drug and device applications within 30 days and allow “reciprocal approval” of therapies from the European Union, Israel, Australia, Canada, and Japan.
In previous years, health advocates and FDA observers have noted pitfalls with the idea. For one thing, the idea of giving a political body such as Congress the power to overrule the FDA’s scientific experts on matters relating to public health, safety, efficacy, science, and other concerns raises major concerns.
Cruz, like some other conservatives, say that US patients don’t have speedy access to possible life-saving treatments. In a previous press release about the RESULTS Act, he said it is time for a “supply-side medical revolution.”
Last year, conservatives saw one related victory with the passage of the so-called right-to-try law. The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 creates an alternative pathway for dying patients who do not qualify for a clinical trial. The law bypasses the FDA's current expanded access and compassionate use programs and allows patients to appeal directly to drug companies.
That law, too, was based on the idea that the FDA does not move quickly enough.
The FDA approved 59 drugs in 2018, compared with 46 in 2017. Other studies have said that the FDA acts on applications more quickly than other regulatory authorities.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.